BRIEF—Brexit's impact on pharma industry – GlobalData views

With Brexit day on the horizon, Gavin Davidson, pharma analysts at analytics firm GlobalData, offers his views as to how this will impact the pharma sector.

“GlobalData’s latest report, ‘Brexit and the Healthcare Industry – Implications for Pharma, Q4 2018’ reveals that 66% of participants across the US, UK, and EU said that it would take more than three years for the UK to stabilize its healthcare industry. This stabilization is of high importance, with the UK pharmaceutical industry contributing £70 billion [~$92 billion] to the economy,” said Mr Davidson.

“Without a free trade deal being agreed upon prior to departure, the UK would no longer have access to the EU single market, meaning pharmaceutical companies, such as AstraZeneca and GlaxoSmithKline, and patients on the NHS that are dependent on imported medications are stockpiling medications,” he added.